|
TBC1D14 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.53539999498054E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.76600000470984E-08 |
| Normal-vs-Stage2 |
7.361800E-03 |
| Normal-vs-Stage3 |
2.5074999999708E-06 |
| Normal-vs-Stage4 |
7.34009999447949E-08 |
| Stage1-vs-Stage2 |
3.083400E-01 |
| Stage1-vs-Stage3 |
6.415000E-01 |
| Stage1-vs-Stage4 |
1.855230E-01 |
| Stage2-vs-Stage3 |
2.186800E-01 |
| Stage2-vs-Stage4 |
6.913600E-02 |
| Stage3-vs-Stage4 |
3.766400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.50509999702942E-08 |
| Normal-vs-AfricanAmerican |
4.159800E-04 |
| Normal-vs-Asian |
1.370580E-04 |
| Caucasian-vs-AfricanAmerican |
7.821200E-01 |
| Caucasian-vs-Asian |
7.020600E-01 |
| AfricanAmerican-vs-Asian |
5.919000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.79560000002877E-07 |
| Normal-vs-Female |
6.78539999743322E-08 |
| Male-vs-Female |
6.982000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.59100000530455E-08 |
| Normal-vs-Age(41-60Yrs) |
4.1665000000024E-05 |
| Normal-vs-Age(61-80Yrs) |
1.60549995520398E-09 |
| Normal-vs-Age(81-100Yrs) |
1.305610E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.410600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.160000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.891400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.701600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.452000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.681230E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.002000E-01 |
| Classical-VS-Follicular |
4.818800E-03 |
| Classical-VS-Other |
2.741200E-01 |
| Classical-VS-Normal |
3.59220000001326E-06 |
| Tall-VS-Follicular |
6.288200E-01 |
| Tall-VS-Other |
7.108200E-01 |
| Tall-VS-Normal |
1.371780E-04 |
| Follicular-VS-Other |
9.038800E-01 |
| Follicular-VS-Normal |
8.81859999468659E-08 |
| Other-VS-Normal |
1.106060E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.85179999998309E-06 |
| Normal-vs-N1 |
3.14640002940791E-09 |
| N0-vs-N1 |
1.881850E-02 |
|
|
